Skip to Main Content

Author Details

Julio Scharfstein
Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro
1978
105
36
Andrej Sali (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36631939High mobility group box 1, ATP, lipid mediators, and tissue factor are elevated in COVID-19 patients: HMGB1 as a biomarker of worst prognosis.Clin Transl Sci2023
37109224Genetic Ablation and Pharmacological Blockade of Bradykinin B1 Receptor Unveiled a Detrimental Role for the Kinin System in Chagas Disease Cardiomyopathy.J Clin Med2023
36960058Pleiotropic antifibrotic actions of aspirin-triggered resolvin D1 in the lungs.Front Immunol2023
36809354Protective effect of Chromobacterium violaceum and violacein against bone resorption by periodontitis.Clin Oral Investig2023
35215131Sheltered in Stromal Tissue Cells, <i>Trypanosoma cruzi</i> Orchestrates Inflammatory Neovascularization via Activation of the Mast Cell Chymase Pathway.Pathogens2022
35544861Brazilian immunology in Caxambu: beyond vaccination, a tribute to the pioneers of basic research in Chagas disease.Mem Inst Oswaldo Cruz2022
33445640Contact System Activation in Plasma from Dengue Patients Might Harness Endothelial Virus Replication through the Signaling of Bradykinin Receptors.Pharmaceuticals (Basel)2021
33575962P2Y14 Receptor as a Target for Neutrophilia Attenuation in Severe COVID-19 Cases: From Hematopoietic Stem Cell Recruitment and Chemotaxis to Thrombo-inflammation.Stem Cell Rev Rep2021
34500007Surface megalin expression is a target to the inhibitory effect of bradykinin on the renal albumin endocytosis.Peptides2021
33941658Dietary Fiber Drives IL-1β-Dependent Peritonitis Induced by <i>Bacteroides fragilis</i> via Activation of the NLRP3 Inflammasome.J Immunol2021
32450614IL-18R signaling is required for γδ T cell response and confers resistance to Trypanosoma cruzi infection.J Leukoc Biol2020
33042157Mast Cells in Alveolar Septa of COVID-19 Patients: A Pathogenic Pathway That May Link Interstitial Edema to Immunothrombosis.Front Immunol2020
30429052P2X7 receptor-mediated leukocyte recruitment and Porphyromonas gingivalis clearance requires IL-1β production and autocrine IL-1 receptor activation.Immunobiology2019
31058153Kinins Released by Erythrocytic Stages of <i>Plasmodium falciparum</i> Enhance Adhesion of Infected Erythrocytes to Endothelial Cells and Increase Blood Brain Barrier Permeability via Activation of Bradykinin Receptors.Front Med (Lausanne)2019
30080658Oral infection of mice with Fusobacterium nucleatum results in macrophage recruitment to the dental pulp and bone resorption.Biomed J2018
30028741Subverting bradykinin-evoked inflammation by co-opting the contact system: lessons from survival strategies of Trypanosoma cruzi.Curr Opin Hematol2018
28824610Mast Cell Coupling to the Kallikrein-Kinin System Fuels Intracardiac Parasitism and Worsens Heart Pathology in Experimental Chagas Disease.Front Immunol2017
28300547Computer-aided quantification of microvascular networks: Application to alterations due to pathological angiogenesis in the hamster.Microvasc Res2017
28950949G Protein-Coupled Kinin Receptors and Immunity Against Pathogens.Adv Immunol2017
27470973Effect of antihypertensive therapy with angiotensin-converting enzyme inhibitors on chronic periodontitis: a case-control study.Oral Dis2016
26152185A Dual Role for P2X7 Receptor during Porphyromonas gingivalis Infection.J Dent Res2015
24925032Porphyromonas gingivalis fimbriae dampen P2X7-dependent interleukin-1β secretion.J Innate Immun2014
25294952Ecotin-like ISP of L. major promastigotes fine-tunes macrophage phagocytosis by limiting the pericellular release of bradykinin from surface-bound kininogens: a survival strategy based on the silencing of proinflammatory G-protein coupled kinin B2 and B1 receptors.Mediators Inflamm2014
25187655C5a and bradykinin receptor cross-talk regulates innate and adaptive immunity in Trypanosoma cruzi infection.J Immunol2014
23355836The kallikrein-kinin system in experimental Chagas disease: a paradigm to investigate the impact of inflammatory edema on GPCR-mediated pathways of host cell invasion by Trypanosoma cruzi.Front Immunol2013
24092749Novel family of insect salivary inhibitors blocks contact pathway activation by binding to polyphosphate, heparin, and dextran sulfate.Arterioscler Thromb Vasc Biol2013
21797847Trypanosoma cruzi invades host cells through the activation of endothelin and bradykinin receptors: a converging pathway leading to chagasic vasculopathy.Br J Pharmacol2012
23151408Resistance to visceral leishmaniasis is severely compromised in mice deficient of bradykinin B2-receptors.Parasit Vectors2012
22047990Bradykinin enhances Sindbis virus infection in human brain microvascular endothelial cells.Virology2012
22036674Maxadilan, the Lutzomyia longipalpis vasodilator, drives plasma leakage via PAC1-CXCR1/2-pathway.Microvasc Res2012
21884889Infection-associated vasculopathy in experimental chagas disease pathogenic roles of endothelin and kinin pathways.Adv Parasitol2011
20964644Captopril increases the intensity of monocyte infection by Trypanosoma cruzi and induces human T helper type 17 cells.Clin Exp Immunol2010
19283409Perspectives on the Trypanosoma cruzi-host cell receptor interactions.Parasitol Res2009
19621073Protease activated receptor signaling is required for African trypanosome traversal of human brain microvascular endothelial cells.PLoS Negl Trop Dis2009
19687097Kinin danger signals proteolytically released by gingipain induce Fimbriae-specific IFN-gamma- and IL-17-producing T cells in mice infected intramucosally with Porphyromonas gingivalis.J Immunol2009
19753474Back to the future in Chagas disease: from animal models to patient cohort studies, progress in immunopathogenesis research.Mem Inst Oswaldo Cruz2009
19176972Salivary gland homogenates of Lutzomyia longipalpis and its vasodilatory peptide maxadilan cause plasma leakage via PAC1 receptor activation.J Vasc Res2009
19293401Proteolytic generation of kinins in tissues infected by Trypanosoma cruzi depends on CXC chemokine secretion by macrophages activated via Toll-like 2 receptors.J Leukoc Biol2009
18201565The role of conserved residues of chagasin in the inhibition of cysteine peptidases.FEBS Lett2008
18979626Angiotensin-converting enzyme limits inflammation elicited by Trypanosoma cruzi cysteine proteases: a peripheral mechanism regulating adaptive immunity via the innate kinin pathway.Biol Chem2008
18512348Roles of naturally occurring protease inhibitors in the modulation of host cell signaling and cellular invasion by Trypanosoma cruzi.Subcell Biochem2008
18318460A recombinant form of chagasin from Trypanosoma cruzi: inhibitory activity on insect cysteine proteinases.Pest Manag Sci2008
17502099The structure of chagasin in complex with a cysteine protease clarifies the binding mode and evolution of an inhibitor family.Structure2007
18052532Bradykinin B2 Receptors of dendritic cells, acting as sensors of kinins proteolytically released by Trypanosoma cruzi, are critical for the development of protective type-1 responses.PLoS Pathog2007
17635790Kininogens coordinate adaptive immunity through the proteolytic release of bradykinin, an endogenous danger signal driving dendritic cell maturation.Scand J Immunol2007
17298440The propeptide of cruzipain--a potent selective inhibitor of the trypanosomal enzymes cruzipain and brucipain, and of the human enzyme cathepsin F.FEBS J2007
16203170Interplay between parasite cysteine proteases and the host kinin system modulates microvascular leakage and macrophage infection by promastigotes of the Leishmania donovani complex.Microbes Infect2006
16998589Blood-brain barrier traversal by African trypanosomes requires calcium signaling induced by parasite cysteine protease.J Clin Invest2006
17056563Cooperative activation of TLR2 and bradykinin B2 receptor is required for induction of type 1 immunity in a mouse model of subcutaneous infection by Trypanosoma cruzi.J Immunol2006
16734782The substrate specificity of cruzipain 2, a cysteine protease isoform from Trypanosoma cruzi.FEMS Microbiol Lett2006
  • 1 - 50 of 105

Recommended Authors

University of Arizona
Career Start Year 2011
Number of shared co-authors 1
Department of Pharmaceutical Chemistry , University of California san francisco
Career Start Year 2011
Number of shared co-authors 1
University of California los angeles
Career Start Year 2010
Number of shared co-authors 0
CSIR - National Chemical Laboratory
Career Start Year 2008
Number of shared co-authors 1
Johns Hopkins University School of Medicine
Career Start Year 2004
Number of shared co-authors 0
University of Nebraska at Omaha
Career Start Year 2003
Number of shared co-authors 1
University of Virginia School of Medicine
Career Start Year 2003
Number of shared co-authors 0
University of California los angeles
Career Start Year 2001
Number of shared co-authors 0
School of Pharmaceutical Sciences of Ribeirao Preto, University of Sao Paulo
Career Start Year 2000
Number of shared co-authors 0
Department of Pharmaceutical Chemistry, University of California san francisco
Career Start Year 1999
Number of shared co-authors 2
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Career Start Year 1996
Number of shared co-authors 0
RWTH Aachen University
Career Start Year 1995
Number of shared co-authors 3
Universidad Nacional de San Martin
Career Start Year 1995
Number of shared co-authors 1
Texas A&M University, College Station
Career Start Year 1995
Number of shared co-authors 0
Qassim University
Career Start Year 1994
Number of shared co-authors 6
Institute of Chemistry, University of Sao Paulo
Career Start Year 1994
Number of shared co-authors 0
School of Public Health, University of California berkeley
Career Start Year 1990
Number of shared co-authors 1
Yale University School of Medicine
Career Start Year 1989
Number of shared co-authors 1
Morehouse School of Medicine
Career Start Year 1988
Number of shared co-authors 0
Weill Cornell School of Medicine
Career Start Year 1988
Number of shared co-authors 0
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California
Career Start Year 1987
Number of shared co-authors 6
Clinical Trials Group
Career Start Year 1986
Number of shared co-authors 0
University of California san francisco
Career Start Year 1986
Number of shared co-authors 0
University of Washington
Career Start Year 1986
Number of shared co-authors 1
Boler-Parseghian Center for Rare and Neglected Disease, University of Notre Dame
Career Start Year 1982
Number of shared co-authors 0
Heidelberg University Biochemistry Center
Career Start Year 1982
Number of shared co-authors 1
Center for Emerging and Re-emerging Infectious Diseases, University of Washington
Career Start Year 1982
Number of shared co-authors 2
university of california san diego Health
Career Start Year 1976
Number of shared co-authors 3
Nursing and Health SciencesMonash UniversityClaytonVictoriaAustralia.
Career Start Year 1975
Number of shared co-authors 1
Lydia Becker Institute for Immunology & Infection, University of Manchester
Career Start Year 1974
Number of shared co-authors 0

Collaborators

Skane University Hospital, Lund University
Co-authored papers 3
Co-authored papers 3
Co-authored papers 3
Leibniz-Forschungsinstitut fur Molekulare Pharmakologie
Co-authored papers 2
Instituto Goncalo Moniz
Co-authored papers 1
Institute of Chemistry, Federal University of Rio de Janeiro
Co-authored papers 1
Co-authored papers 1
University of California San Francisco
Co-authored papers 1
The Joint Center for Structural Genomics, Stanford University
Co-authored papers 1
Pfizer Inc.
Co-authored papers 1
New York University School of Medicine
Co-authored papers 1
National Cancer Institute, National Institutes of Health
Co-authored papers 1
Monash University
Co-authored papers 1
National Centre for Cell Science, SP Pune University Campus
Co-authored papers 1
University of California San Francisco
Co-authored papers 1
University of California san francisco
Co-authored papers 1
National Institute on Aging, National Institutes of Health
Co-authored papers 1
Instituto de Biofisica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro
Co-authored papers 1
University of California at San Francisco
Co-authored papers 1
Sandler Center for Drug Discovery, University of California San Francisco
Co-authored papers 1
Institute of Chemistry, Federal University of Rio de Janeiro
Co-authored papers 1
University of Colorado School of Medicine Aurora
Co-authored papers 1